Loading...
Number of patients with adverse events by system organ class and preferred term
Number of patients with serious adverse events by system organ class and preferred term
measured by laboratory and vital sign variables over time including change from baseline
Assessed by overall response rate (ORR) defined as the proportion of patients who have a confirmed complete or partial radiological response by the Investigator according to RECIST v1.1 (for patients in the dose expansion cohorts, only)
Number of patients with at least 1 dose-limiting toxicity (DLT), which is any toxicity defined as a DLT in the Clinical Study Protocol
The percentage or number of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST v1.1)
The time from date of first response until date of disease progression or last evaluable assessment (RECIST v1.1) in the absence of progression
The percentage of patients with confirmed CR or PR or having SD maintained (RECIST v1.1) for >=11 weeks from first dose
The time from first dose until RECIST 1.1 defined disease progression or death due to any cause
The time from the date of the first dose of study treatment until death due to any cause.
Measurement of plasma concentrations of AZD9592, total antibody and total unconjugated warhead
Measurement of PK parameters: Area under the concentration time curve (AUC)
Measurement of PK parameters: Maximum observed plasma concentration of the study drug (C-max)
Measurement of PK parameters: Time to maximum observed plasma concentration of the study drug (T-max)
Measurement of PK parameters: the volume of plasma from which the study drug is completely removed per unit time (Clearance)
Measurement of PK parameters: Terminal elimination half-life (t 1/2)
Evaluating the number and percentage of patients who develop Anti-drug antibody (ADA) during treatment